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Abstract
Background—As evidence-based guidelines increasingly define standards of care, the accurate 
reporting of patterns of treatment becomes critical to determine if appropriate care has been 
provided. We explore the level of agreement between claims and record abstraction for treatment 
regimens for prostate cancer.
Methods—Medicare claims data were linked to medical records abstraction using data from the 
Centers for Disease Control and Prevention’s National Program of Cancer Registry–funded Breast 
and Prostate Patterns of Care study. The first course of therapy included surgery, radiation therapy 
(RT), and hormonal therapy with luteinizing hormone–releasing hormone agonists.
Results—The linked sample included 2765 men most (84.7%) of whom had stage II prostate 
cancer. Agreement was excellent for surgery (κ = 0.92) and RT (κ = 0.92) and lower for hormonal 
therapy (κ = 0.71); however, most of the discrepancies were due to greater number of patients 
reported who received hormonal therapy in the claims database than in the medical records 
database. For some standard multicomponent management strategies sensitivities were high, for 
example, hormonal therapy with either combination RT (86.9%) or cryosurgery (96.6%).
Conclusions—Medicare claims are sensitive for determining patterns of multicomponent care 
for prostate cancer and for detecting use of hormonal therapy when not reported in the medical 
records abstracts.
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Evidence-based guidelines for prostate cancer that are derived from clinical trials can 
improve outcomes of care. As the treatment for prostate cancer is changing rapidly, 
particularly with regard to radiation therapy (RT), multiple approaches based on life 
expectancy, comorbidities, and quality of life, might be considered appropriate. The 
comparative effectiveness of various approaches can be studied at the population level.1 
Although cancer registries, by design, are not set up to obtain comprehensive and quality-
controlled treatment data, enhanced data can be obtained by reabstraction of hospital data 
and contact with physician and outpatient facilities. Such reabstraction can secure more 
complete information on RT, chemotherapy, and hormonal therapy, as was done in the 
Centers for Disease Control and Prevention National Program of Cancer Registries Patterns 
of Care for Breast and Prostate Cancer study. In contrast, Claims databases are structured to 
capture all therapies for the purpose of billing, but may be difficult to consolidate for a given 
patient and have other limitations, which have been discussed in the literature.2–8
Previous studies have generally shown a high level of agreement between claims and 
records.9–16 There is little evidence, however, regarding whether treatment regimens with 
multiple components (surgery, radiation, and hormonal therapy) or specific kinds of RT have 
as high a level of agreement. We aimed to examine the level of agreement between Medicare 
claims and record review for treatment of prostate cancer. This study advances the literature 
by comparing data from the 2 sources for single and multiple component prostate cancer 
therapy, and by examining specific types of RT for this disease.
METHODS
The Centers for Disease Control and Prevention (CDC) National Program of Cancer 
Registries (NPCR) patterns of care for breast and prostate cancer study (POCBP) was the 
source of data for this study. Data related to the diagnosis and treatment of breast and 
prostate cancers diagnosed in 2004 were reabstracted from hospitals, radiation facilities, and 
oncologists’ offices in 7 states (California, Georgia, Kentucky, Louisiana, Minnesota, North 
Carolina, and Wisconsin), including 9017 randomly selected cases of invasive prostate 
cancer (C61.9). Minorities and Appalachian residents were over sampled. Cases diagnosed 
at Veterans Affairs hospitals and through autopsies or deaths certificates were excluded. 
Institutional Review Board approval was secured from 5 of the 7 states to send unique 
patient identifiers to the Centers for Medicare and Medicaid Services to link POCBP data 
with Medicare claims. Medicare is the primary insurer for 97% of the US population aged 
65 years and older, covering inpatient hospital care (part A) and outpatient care and 
physician services (part B). There were 6862 men with prostate cancer from the 5 
participating states. Records for these men were linked to claims data to capture treatment in 
the 12 months after diagnosis. We excluded 2968 patients because they were under 65 years 
of age. Another 1129 patients were excluded because they had incomplete Medicare 
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coverage, managed care enrollment, or lack of Medicare claims. The final sample was 2765 
patients.
TREATMENT ASSESSMENT MEDICAL RECORDS
The overall goal of the POCBP study was to ascertain whether or not the patient had 
received guideline-concordant care based on National Comprehensive Cancer Network 
guidelines for prostate cancer17 in their year of diagnosis. To obtain complete treatment data 
to assess quality of care, registries reviewed not only hospital medical records but also 
outpatient records when there was no adequate information to determine guideline-
concordant care.
Definitions of Treatment
We used the standard North American Association of Central Cancer Registries data 
collection rules (http://seer.cancer.gov/tools/codingmanuals/historical.html) to gather 
information on first course of treatment and defined it as the therapy regimen that is given or 
planned. First course of treatment could extend up to 1 year or more after cancer diagnosis. 
We categorized surgery as: (1) prostatectomy (simple, subtotal, segmental, or radical); (2) 
cryosurgery; (3) hyperthermia, laser surgery, radiofrequency ablation, or microwave. We 
differentiated RT into: (1) external beam (including 3D combination RT); (2) brachytherapy; 
and (3) combination of external beam and brachytherapy, seed, or radiotherapy. Hormonal 
therapy was based on receipt of luteinizing hormone–releasing hormone (LHRH) agonists 
including goserelin acetate, leuprolide, and leuproliden implants.
Other Covariates
Covariates in the multivariate models were AJCC stage (stages I, II, III, or IV),18 
comorbidity score from the ACE-27 comorbidity index (none, mild, moderate, or severe),19 
age (65–74 vs. 75+ y), urban/rural location, race/ethnicity (White, non-Hispanic; Black, 
non-Hispanic; American Indian/Alaska Native (AI/AN), non-Hispanic, Asian/Pacific 
Islander (API), non-Hispanic, Hispanic), source of payment (Medicaid, private insurance, or 
none vs. Medicare or other public payer), source of medical records (hospital chart only not 
requiring physician verification, no verification of physician offices, or unified chart vs. 1 or 
more physician offices), and cancer registry.
TREATMENT ASSESSMENT CLAIMS
We derived treatment information from all available Medicare claims files (hospital, 
outpatient, physician, hospice, home health, durable medical equipment, and skilled nursing) 
during a 1-year time window after cancer diagnosis. Service codes categorize services by 
type. We only used claims from the physician file with a service code of medical, surgical, 
or consultation, and thereby assume that such claims were more likely to be recorded or 
“directed” by physicians. Claims with other service codes, for example, radiology and 
laboratory, were excluded. Treatments were classified similar to their medical record 
counterparts but on the basis of International Classification of Diseases,20 Current Procedure 
Terminology,21 or Healthcare Common Procedure Coding System codes (Appendix 1).
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STATISTICAL ANALYSIS
We reported patient, payer, and sociodemographic characteristics of our included sample and 
those patients who were excluded from the analysis, and tested for significant differences. 
We assessed agreement between the Medicare claims and POCBP-abstracted medical 
records for surgery, radiation, and LHRH hormonal therapy, and calculated the sensitivity of 
the Medicare claims data using the POCBP medical records as the “gold standard.” We 
assessed reliability by calculating the κ statistic for each treatment component, and various 
combinations of these components, and interpreted the κ statistics according to the 
following22: excellent (0.81–1.00), substantial (0.61–0.80), moderate (0.41–0.60), fair 
(0.21–0.40), slight (0.00–0.20), and <0.00 (poor). We also assessed sensitivity of the claims 
data when using different sources of Medicare claims (eg, inpatient only and inpatient plus 
physician.) Finally, we estimated 3 multivariate logistic regressions for the 3 treatment 
outcomes (surgery, radiation, and LHRH hormonal therapy) to identify predictors of 
agreement between claims and records for surgery, radiation, or LHRH agonist therapy. SAS 
version 9.2 and 9.3 was used in all analyses.
RESULTS
Patient characteristics of men aged 65+ whose records were linked to Medicare claims and 
those who were not able to be linked for various reasons are shown in Table 1. There were 
statistically significant differences between the study sample and those not included in the 
study with respect to age, stage, payer, urban/rural location, registry, and race/ethnicity. In 
particular, cases not included in the study were more likely Hispanic and API, private pay or 
uninsured, from urban areas, and residents of 1 urban registry from a state with high 
proportion of HMO patients (P < 0.01 for race, payer, urban/rural location, and registry).
When Medicare claims were compared with records abstraction (Table 2), the κ statistics for 
surgery and RT were high (0.92 and 0.92, respectively) as were the sensitivities of claims 
using records as the gold standard for all of the surgical or RT options overall (96.8% and 
96.2%, respectively). For detecting treatment with LHRH agonists, overall sensitivity of 
claims was high (95.3%) and κ was 0.71. As LHRH agonists are administered in the 
outpatient setting, it was of interest to find that there were 335 cases (or nearly 27%) where 
claims indicated use of LHRH agonists but medical records did not, compared with 47 (5%) 
for which use was only indicated in the medical records data. When the analysis was 
stratified by state (unreported) for LHRH, the percentage of claims not documented by 
records ranged from 21.6% to 40.8% across the 5 states, and the percentage of records not 
represented by claims ranged from 0% to 11.8%. The sensitivities of individual local 
treatment modalities were nearly as high as the overall treatment categories with the 
exception of the category of the less commonly used treatments of laser ablation, 
hyperthermia, radiofrequency, or microwave treatments.
The most common single and combination treatment options were external beam radiation 
with LHRH agonists, radical prostatectomy only, and LHRH agonists only (Table 3). The 
highest sensitivities are reported for cryosurgery with LHRH agonists (96.6%) and radical 
prostatectomy alone (91.9%). Relatively low sensitivities were found for some regimens, 
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including external beam radiation only (56.6%), combination RT alone (77.2%), 
brachytherapy with hormonal therapy (73.7%), and the no treatment option (64.7%).
The effect of using different sources of claims data (Table 4) show that Medicare hospital 
claims only were unable to identify hyper/laser surgery, any kind of RT, and LHRH agonists. 
For surgery, sensitivity for radical prostatectomy was high with hospital files alone and not 
substantially improved with additional files. For cryosurgery, sensitivity improved after 
adding physician files to hospital files. Sensitivity for external beam radiation and 
combination RT improved substantially when outpatient files were added to hospital and 
physician files, although additional files did not improve sensitivity for brachytherapy.
We conducted 3 separate multivariate logistic regression models to predict concordance 
between claims and records for (1) any surgery, (2) any radiation, and (3) hormonal therapy 
(Table 5). All regression models included covariates for state registries, comorbidity burden, 
age, location (urban, rural, and mix), race/ethnicity, source of payment, and abstraction 
method. Those with mild or severe comorbidity (vs. none) or stage 1 prostate cancer (vs. 4) 
were less likely to have concordance for surgery [odds ratio (OR) = 0.677, 0.400, and 0.212, 
respectively]. Younger men were much more likely to have concordance (OR = 2.245) and 
those whose records were abstracted from hospital charts only had half the odds of 
concordance for surgery (OR = 0.547). The odds of agreement for RT from both sources of 
data were lower for patients with stage 2 (vs. 4) disease (OR = 0.270). The odds of 
concordance for hormonal therapy was higher for those with stage 1 or 2 (vs. 4) but lower 
for those with a source of payment of Medicaid (vs. Medicare and other public insurances) 
(OR = 4.336, 2.627, and 0.653, respectively).
DISCUSSION
We compared Medicare claims to medical record review as sources for information on 
treatment regimens for prostate cancer. The results showed that claims are a sensitive source 
of information even for multicomponent treatment strategies including specific types of 
surgery or radiation and hormonal therapy. Findings regarding the sensitivity of Medicare 
claims using records as the gold standard for different prostate cancer regimens have not 
been previously reported. Moreover, the excess of claims over records for LHRH agonists 
suggests that claims could be an additional source of information on this important treatment 
modality.
Our findings of a high level of agreement between claims and record review for detecting 
prostate cancer surgery and RT overall are generally consistent with the literature.
Although there is some discordance between medical claims compared with chart review or 
tumor registry data with respect to type of surgery, receipt of chemotherapy, and radiation, 
previous studies have found agreement to be relatively high between the 2 sources for single 
therapies. This has been demonstrated for prostate, breast, and other cancers.9–13 For 
example, Virnig et al13 reported κ statistics of 0.84–0.89 for prostate cancer treatment when 
comparing Medicare claims to Surveillance, Epidemiology, and End Results (SEER) data, 
with slightly higher rates of agreement for radical surgery versus resection or no surgery/
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biopsy. Virnig et al13 showed that radiotherapy for prostate cancer also seems to be 
consistently reported in both claims and medical records. A comparison of any radiation 
treatment on Medicare claims to radiation treatment reported by the SEER program found a 
level of agreement of 93.1% for prostate cancer with a κ statistic of 0.85.
We found the sensitivity of Medicare claims to records for hormonal therapy using LHRH 
agonists to be 95.3%, and that Medicare claims identified about one-third more patients with 
this therapy than record review (1247 vs. 959 patients). Kuo et al23 studied GnRH agonists 
use in men with SEER-Medicare data. They found that 8.9% of incident GnRH users had no 
prostate cancer diagnosis in SEER data, and that GnRH users without a tumor registry 
diagnosis were more likely to be older, black, and have comorbidities; factors that are 
probably typical of patients with incomplete diagnostic evaluations for cancer.16,24,25 Our 
finding that claims data are an important source of information on hormonal therapy 
complements the work of Kou and suggests that these data are useful as both diagnosis and 
treatment indicators.
Use of additional Medicare files compared with hospital claims alone improved the 
comparability of claims with medical records for all therapies except for radical 
prostatectomy, where hospital claims alone provided a high level of sensitivity. This was 
particularly true for cryosurgery (62.8% sensitivity with hospital claims only, 95.6% 
sensitivity with hospital, physician, and outpatients claims). Moreover, radiation and 
hormonal therapy could only be identified from physicians and/or outpatient claims. 
Furthermore, for RT, physician files alone were only adequate for brachytherapy, whereas 
for external beam or combination RT, outpatient files substantially improved sensitivity.
A modest level of agreement was found for some specific treatment regimens. For example, 
nearly 27% of LHRH therapy recognized in claims was not recognized by record review. 
The scope and method of data collection of the POCBP study may be a factor. Although 
medical record abstraction is considered by most the “gold standard” of first course of 
treatment, such abstraction often focuses only on the hospital record.22 By contrast, the 
POCBP abstractors also reviewed outpatient data for most cases. This notwithstanding, the 
claims data indicate that there were components of care that may have been missed by chart 
reviews. That there are claims undocumented in the medical record is therefore not 
surprising given that there was variability in the extent to which the registries pursued 
outpatient records from radiation facilities and oncologist offices. As LHRH is commonly 
administered in an outpatient setting, these therapies may have been missed in the 
reabstraction from registries than were less aggressive in the pursuit of outpatient records. In 
addition, the medical record abstraction was directed toward first course of treatment 
regimens, whereas Medicare claims were reviewed within a predefined time window of 1 
year. Therefore as we could not discern the endpoint for first course of therapy in claims, 
Medicare claims could not distinguish between adjuvant/curative RT and palliative RT. If 
first course of treatment exceeded 1 year, the treatment would be recognized by record 
review but not by claims. This may lead to an underestimate of agreement and sensitivity of 
claims to records; however, this did not seem to be reflected in our data as sensitivity was 
uniformly high and when there was disagreement between the 2 sources, it was more likely 
that the treatment was reported in the Medicare data than in the medical records. We also 
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found that no treatment was much more likely to be suggested by medical records and that 
hormonal therapy and radiation were much more likely to be suggested by claims. At least 
some of this discordance could reflect active surveillance followed by a second course of 
treatment or palliative care after progression. In such cases, medical records would have no 
treatment recorded as only the first course of treatment is abstracted, but claims would pick 
up subsequent courses of treatment and palliative care occurring in the first year.
The multivariate analyses to identify predictors of concordance was only somewhat 
elucidating. It is unclear why comorbidity burden or earlier stage of disease would lead to 
less agreement, except to the extent that such patients may be more likely to be treated in an 
outpatient setting only. This would be supported by the finding that reabstraction from 
hospital charts only had half the odds of concordance compared with patients whose records 
abstraction included at least 1 physician office.
We are aware of both strengths and weaknesses of our study. Strengths include the large 
sample size and geographic diversity, including data from 5 different states. Moreover, the 
POCBP study used a thorough method of chart review,26 with reabstraction of hospital 
records and contact with doctors’ offices. The follow-up was active and more focused for 
treatment information than registries funded by the CDC’s NPCR. Thus inclusion of 
treatment information from the medical record review in this study should be more complete 
than that obtained routinely by both SEER and NPCR tumor registries.
Limitations include the timing of the POCBP abstracting (nearly 5 y after diagnosis when 
some records may have been no longer available), and the inability to control for 
incongruities between the initial course of treatment time window for records and the 1-year 
time frame for Medicare claims. Limitations associated with the claims data include the 
purpose of claims being primarily for reimbursement,2 the bundling of some procedures into 
office visits,3 providers failing to bill for some procedures,4,5 the underreporting of chronic 
disease, other underlying conditions, or procedures that do not result in additional 
reimbursement,6,7 and coding errors.8,27–30 Finally, the study is limited to men 65 years and 
older, those with complete Medicare coverage, and no managed care involvement.
In conclusion, claims are a readily available, inexpensive, and convenient source of data for 
epidemiologic research, and we have shown that, for prostate cancer, they provide greater 
coverage of hormonal therapy, which is often delivered in the outpatient setting. Medical 
record review is considerably more expensive and logistically difficult. Although it has the 
reputation of being a more sensitive metric for identifying treatment patterns, it is not 
without flaws.31 It would seem prudent at this juncture to establish the extent to which 
claims are an acceptable, accurate, and sensitive source of specific cancer treatment 
regimens. As Medicare claims are a highly sensitive source of information on surgery, 
radiation, and hormonal therapy for prostate cancer compared with medical records, we 
suggest using claims as a supplement to registry data, the utility of which has been 
demonstrated by others16 or when collection of complete treatment data through medical 
record review is unfeasible.
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APPENDIX 1
TABLE A1
Description of Treatment Based on Medicare Claims—Prostate Cancer
Treatment Category Treatment Type Procedures
Surgery Subtotal, segmental, or simple prostatectomy ICD: 603, 604
CPT: 55801, 55821, 55831
Radical prostatectomy ICD: 605
CPT: 55810, 55812, 55815, 55840, 
55842, 55845, 55866
Prostatectomy NOS ICD: 606, 6061, 6062, 6069
CPT: 55899
Cryoprostatectomy/cryosurgery+TURP ICD: 6062
CPT: 55873
Laser ablation/hyperthermia/radiofrequency, microwave ICD: 6096, 6097
CPT: 53850, 53852, 52647, 52648, 
55853
ICD:
Other laparoscopic CPT: 55866
Hormonal therapy LHRH agonists CPT: J9202, J9217, J9218, J9219
Radiation Not otherwise specified CPT: 0073T, 77371, 77372, 77373, 
G0174
External beams CPT: 77401–77423, 77520, 77522, 
77523, 77525
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Treatment Category Treatment Type Procedures
Brachytherapy CPT 77326–77328, 77776–77778, 
77781–77784, 77790, 77799, 
19296, 19298, 19499, 55859
Radiotherapy CPT: 79005, 79101, 79200, 79300, 
79440, 79445, 79999
Seed CPT: 55876
Combination therapy Beams and (brachytherapy, seed, or 
radio)
CPT indicates Current Procedure Terminology; ICD, International Classification of Diseases; LHRH, luteinizing hormone–
releasing hormone.
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TABLE 1
Frequency Distribution of Characteristics of Men Aged 65 Years and Older With Prostate Cancer, by Inclusion 
Status; 2765 Prostate Cancer Patients, NPCR POCBP Study
N (%)
Cases Included (n = 2765) Cases Excluded (n = 1129)
Comorbidity score
 None 712 (27.0%) 310 (29.2%)
 Mild 1475 (56.0%) 582 (54.9%)
 Moderate 319 (12.1%) 117 (11.0%)
 Severe 130 (4.9%) 52 (4.9%)
Age*
 65–70 1162 (42.0%) 535 (47.4%)
 71–75 777 (28.1%) 292 (25.9%)
 76–80 504 (18.2%) 195 (17.3%)
 81–85 221 (8.0%) 74 (6.6%)
 > 85 101 (3.7%) 33 (2.9%)
AJCC stage*
 0 5 (0.2%) 2 (0.2%)
 1 78 (2.8%) 38 (3.4%)
 2 2342 (84.7%) 905 (80.2%)
 3 70 (2.5%) 23 (2.0%)
 4 114 (4.1%) 72 (6.4%)
 Missing 156 (5.6%) 89 (7.9%)
Payer*
 Medicare or other public 1673 (62.3%) 431 (39.0%)
 Medicaid 283 (10.5%) 107 (9.7%)
 Private 715 (26.6%) 543 (49.1%)
 None 16 (0.6%) 25 (2.3%)
Urban/rural*
 Urban 1059 (38.5%) 827 (73.8%)
 Rural 528 (19.2%) 48 (4.3%)
 Urban/rural Mix 1164 (42.3%) 246 (21.9%)
Registry*
 California 371 (13.4%) 598 (53.0%)
 Georgia 850 (30.7%) 146 (12.9%)
 Kentucky 239 (8.7%) 30 (2.7%)
 Louisiana 824 (29.8%) 263 (23.3%)
 North Carolina 481 (17.4%) 92 (8.2%)
Race/ethnicity*
 White, non-Hispanic 1635 (59.1%) 369 (32.7%)
 Black, non-Hispanic 887 (32.1%) 388 (34.4%)
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N (%)
Cases Included (n = 2765) Cases Excluded (n = 1129)
 AI/AN, non-Hispanic 15 (0.5%) 2 (0.2%)
 API, non-Hispanic 86 (3.1%) 135 (12.0%)
 Hispanic 142 (5.1%) 235 (20.8%)
*P < 0.01, χ2.
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TABLE 4
Comparing the Sensitivity* of Medicare Claims to Record Abstraction Using Different Sources of Medicare 
Claims: Prostate Cancer Patients, NPCR POCBP Study
Treatment†
Source of Medicare Claims
Hospital (H) Hospital+Physician (HP) Hospital+Physician+Outpatient (HPO) All‡
Surgery (n = 2705) 95.0 96.2 96.8 96.8
 Prostatectomy 98.3 97.5 97.3 97.3
 Cryosurgery 62.8 91.2 95.6 95.6
 Hyper/laser 0.0 58.3 58.3 58.3
Radiation (n = 2700) 0.0 60.6 96.2 96.2
 External beam 0.0 29.3 95.3 95.3
 Brachytherapy 0.0 94.3 95.0 95.0
 Combination 0.0 45.4 93.8 93.8
Hormonal therapy (n = 2690) 0.0 91.4 95.2 95.3
*With the sources of Medicare claims, sensitivity is measured as the percentage of patients with records identified therapies that are confirmed by 
claims.
†Sample size depends on source of claims (H, HP, HPO, All) and treatment type; for surgery (1078, 2698, 2704, and 2705, respectively); for 
radiation (1077, 2693, 2700, and 2700, respectively); for hormonal therapy (1072, 2683, 2690, and 2690, respectively).
‡
The All category includes hospice, home health care, skilled nursing, and durable medical equipment.
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